-

Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023 at 3:45 p.m. PST.

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website. A replay will be available for at least 30 days following the presentation.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Contacts

Charles Liles
cliles@xencor.com
626-737-8118

Industry:

Xencor, Inc.

NASDAQ:XNCR
Details
Headquarters: Pasadena, CA
CEO: Bassil Dahiyat
Employees: 250
Organization: PUB
Release Versions
English

Contacts

Charles Liles
cliles@xencor.com
626-737-8118

More News From Xencor, Inc.

Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 2026 pipeline advancement milestones for its clinical-stage portfolio of novel XmAb® drug candidates. “Xencor designs proteins that enable potential first-in-class and best-in-class medicines for patients, and we are building on momentum from 2025, when we presented...

Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the issuance of U.S. Patent 12,492,253, which covers Xencor’s Xtend™ Fc domain for extending the half-life of antibodies targeting C5, with a term that extends into December 2028. The new patent term is approximately three years longer than the previous latest-to-expire U.S. patent covering...

Xencor to Participate at Upcoming Investor Conferences

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences: TD Cowen Immunology and Inflammation Virtual Summit Date: Wednesday, November 12, 2025 Presentation Time: 3:00 p.m. ET / 12:00 p.m. PT Piper Sandler 37th Annual Healthcare Conference Date: Tuesday, December...
Back to Newsroom